참고문헌
- Ansari R, Gonin R, Socinski M (2007). Eldelry subgroup analysis of a radnomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer. Proc Am Soc Clin Oncol, 25, 7665.
- Ansari RH, Socinski MA, Edelman MJ, et al (2011). A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced nonsmall cell lung cancer. Crit Rev Oncol Hematol, 78,162-71. https://doi.org/10.1016/j.critrevonc.2010.03.003
- Belani CP, Fossella F (2005). Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer, 104, 2766-74. https://doi.org/10.1002/cncr.21495
- Deppermann KM (2011). Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer, 33, 115-20.
- Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer (1999). The elderly lung cancer vinorelbine Italian study group. J Natl Cancer Inst, 91, 66-72. https://doi.org/10.1093/jnci/91.1.66
- Havlik RJ, Yancik R, Long S, et al (1994). The national institute on aging and the national cancer institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74, 2101-6. https://doi.org/10.1002/1097-0142(19941001)74:7+<2101::AID-CNCR2820741718>3.0.CO;2-M
- Hensing TA, Peterman AH, Schell MJ, et al (2003). The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer, 98, 779-88. https://doi.org/10.1002/cncr.11548
- Jatoi A, Hillman S, Stella P, et al (2005). Should elderly nonsmall- cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the north central cancer treatment group. J Clin Oncol, 23, 9113-9. https://doi.org/10.1200/JCO.2005.03.7465
- Kelly K, Giarritta S, Akerley W (2001). Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of southwest oncology trials 9509 and 9308. Proc Am Soc Clin Oncol, 20, 1313.
- Langer C, Vangel M, Schiller HJ (2003). Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol, 22, 2571.
- Langer CJ, Manola J, Bernardo P, et al (2002). Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst, 94, 173-81. https://doi.org/10.1093/jnci/94.3.173
- Maione P, Rossi A, Sacco PC, et al (2010). Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol, 2, 251-60. https://doi.org/10.1177/1758834010366707
- Nurgalieva Z, Xia R, Liu CC, et al (2010). Risk of chemotherapyinduced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung sancer. Am J Ther, 17, 148-58. https://doi.org/10.1097/MJT.0b013e3181a3e50b
- Pallis AG, Gridelli C, Van Meerbeeck JP, et al (2010). EORTC elderly task force and lung cancer group and International society for geriatric oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol, 21, 692-706. https://doi.org/10.1093/annonc/mdp360
- Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
- Ramalingam S, Perry MC, La Rocca RV, et al (2008). Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer, 113, 542-6. https://doi.org/10.1002/cncr.23583
- Repetto L, Venturino A, Fratino L, et al (2003). Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer, 39, 870-80. https://doi.org/10.1016/S0959-8049(03)00062-5
- Rocha Lima CM, Herndon JE, Kosty M, Clamon G, Green MR (2002). Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the cancer and leukemia group B. Cancer, 94, 181-7. https://doi.org/10.1002/cncr.10174
- Schild SE, Stella PJ, Geyer SM, et al (2003). The outcome of combinedmodality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol, 21, 3201-6. https://doi.org/10.1200/JCO.2003.12.019
- Sederholm C, Hillerdal G, Lamberg K, et al (2005). Phase III trial of gemcitabine plus carboplatin versus singleagent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group. J Clin Oncol, 23, 8380-8. https://doi.org/10.1200/JCO.2005.01.2781
- Sequist LV, Lynch TJ (2003). Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol, 21, 3186-8. https://doi.org/10.1200/JCO.2003.04.002
- Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22. https://doi.org/10.1097/00001622-199303000-00010
- Walling J (1994). Chemotherapy for advanced non-small-cell lung cancer. Respir Med, 88, 649-57. https://doi.org/10.1016/S0954-6111(05)80061-7
피인용 문헌
- Prediction of Chemotherapeutic Response in Unresectable Non-small-cell Lung Cancer (NSCLC) Patients by 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) Assay vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3057
- Incidence of Hematologic Toxicity in Older Adults Treated with Gemcitabine or a Gemcitabine-Containing Regimen in Routine Clinical Practice: A Multicenter Retrospective Cohort Study vol.31, pp.10, 2014, https://doi.org/10.1007/s40266-014-0207-z
- A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial vol.17, pp.1, 2016, https://doi.org/10.1186/s13063-016-1231-6